Payment overview · 2025
General Payments
$602.11
31 reported records · 13 companies
Healthcare provider profile · identity verified
Beth A Knox, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FORSYTH, MO · NPI 1831424266
Verified facts
What the public records show
CMS Open Payments records show Beth A Knox, FNP received $602.11 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.78 | 30.9% | 11 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $80.83 | 13.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $64.70 | 10.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.79 | 8.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.82 | 6.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.62 | 5.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.02 | 5.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.11 | 3.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.83 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.42 | 3.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.38 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 2.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.59 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $602.11 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.15 | 5 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $80.83 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $67.05 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $64.70 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $45.08 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.02 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 537 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 521 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 96 |
| Potassium Chloride | Potassium Chloride | 302 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 61 |
| Gabapentin | Gabapentin | 284 | 58 |
| Metformin Hcl | Metformin Hcl | 249 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 59 |
| Omeprazole | Omeprazole | 228 | 56 |
| Losartan Potassium | Losartan Potassium | 215 | 58 |
| Furosemide | Furosemide | 209 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 206 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 53 |
| Simvastatin | Simvastatin | 180 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 43 |
| Trazodone Hcl | Trazodone Hcl | 163 | 34 |
| Sertraline Hcl | Sertraline Hcl | 145 | 36 |
| Ozempic | Semaglutide | 139 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 27 |
| Eliquis | Apixaban | 124 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 28 |
| Montelukast Sodium | Montelukast Sodium | 108 | 24 |
| Allopurinol | Allopurinol | 104 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 23 |
| Carvedilol | Carvedilol | 93 | 22 |
| Meloxicam | Meloxicam | 93 | 20 |
| Buspirone Hcl | Buspirone Hcl | 88 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 18 |
| Finasteride | Finasteride | 82 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 20 |
| Jardiance | Empagliflozin | 76 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 18 |
| Metformin Hcl Er | Metformin Hcl | 76 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 20 |
| Glimepiride | Glimepiride | 68 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 57 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 15 |
| Prednisone | Prednisone | 56 | 46 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Famotidine | Famotidine | 54 | 14 |
| Alendronate Sodium | Alendronate Sodium | 52 | 13 |
| Atenolol | Atenolol | 52 | 11 |
| Novolog Flexpen | Insulin Aspart | 52 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 20 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Spironolactone | Spironolactone | 50 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Baclofen | Baclofen | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 37 |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Glipizide | Glipizide | 42 | 12 |
| Bupropion Xl | Bupropion Hcl | 41 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Nystatin | Nystatin | 39 | 14 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $602.11 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE, JARDIANCE, MAVYRET, Ozempic, REXULTI, Rybelsus, Senza, The Cologuard Plus Collection Kit, VRAYLAR, Veozah, Wegovy, YUPELRI, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error